The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if ...

On the one hand, its impressive business performance can make investors ponder potential life-changing investment returns. Conversely, feeling confident in Hims & Hers Health can sometimes be ...

On the flip side, the success of GLP-1 receptor agonists is sparking renewed interest in general medicines, with companies ...

Glucagon-like agonists (GLP-1s ... The success that some achieve using GLP-1s can come with a price – both financially and ...

2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and ...